Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560484890> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2560484890 endingPage "1057" @default.
- W2560484890 startingPage "1057" @default.
- W2560484890 abstract "Abstract Abstract 1057 Acute myeloid leukemia (AML) cells depend on endothelial cells for survival and proliferation. By targeting endothelial cells with a novel vascular disrupting agent, we recently demonstrated regression of AML (Madlambayan, et al., Blood 2010). In an effort to discover a more selective, anti-vascular therapy for leukemia, we hypothesized that targeting endothelial cell-derived paracrine and leukemia cell-derived autocrine growth factors would result in regression of disease. In particular, our strategy focused on vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and stem cell factor (SCF), which are known to promote leukemia cell proliferation. Receptors for each of these growth factors are potently inhibited by pazopanib, which is an orally available tyrosine kinase inhibitor. The aim of our study was to determine the dependence of leukemia cell survival and proliferation on the combined receptor signaling of VEGF, PDGF and SCF. Leukemia cell lines (KG-1, HL60 and K562) were incubated at various durations with varying concentrations of pazopanib. Leukemia cell proliferation was quantified using XTT assay. Apoptosis induction was analysed by flow cytometry (Annexin V and PI staining). Pazopanib effectively impaired proliferation in leukemia cells in vitro in a dose and time dependent fashion. During a 16-hour incubation of leukemia cells, pazopanib showed a 50% lethal concentration (LC50) of 22.57 μM (r = .986), 41.6 μM (r = .991), and 81.97 μM (r = .996) for HL60, K562, and KG-1 cells, respectively. Staining with Annexin V and PI identified apoptosis as the main cause of cell death after exposure to pazopanib. The IC50 of apoptosis for HL60 cells was 132.5 ± 2.7 μM (p = 0.0002). These results indicate that leukemia cells depend on the combined signaling of VEGF, PDGF, and SCF, and suggest that selective inhibition by pazopanib may be a promising therapeutic for AML. Furthermore, pazopanib is orally available and associated with minimal side effects, thus representing an attractive candidate for further testing in AML. Disclosures: No relevant conflicts of interest to declare." @default.
- W2560484890 created "2016-12-16" @default.
- W2560484890 creator A5008234068 @default.
- W2560484890 creator A5013568540 @default.
- W2560484890 creator A5036459791 @default.
- W2560484890 creator A5042492175 @default.
- W2560484890 creator A5057316768 @default.
- W2560484890 creator A5069302338 @default.
- W2560484890 date "2010-11-19" @default.
- W2560484890 modified "2023-09-26" @default.
- W2560484890 title "Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib." @default.
- W2560484890 doi "https://doi.org/10.1182/blood.v116.21.1057.1057" @default.
- W2560484890 hasPublicationYear "2010" @default.
- W2560484890 type Work @default.
- W2560484890 sameAs 2560484890 @default.
- W2560484890 citedByCount "3" @default.
- W2560484890 countsByYear W25604848902020 @default.
- W2560484890 crossrefType "journal-article" @default.
- W2560484890 hasAuthorship W2560484890A5008234068 @default.
- W2560484890 hasAuthorship W2560484890A5013568540 @default.
- W2560484890 hasAuthorship W2560484890A5036459791 @default.
- W2560484890 hasAuthorship W2560484890A5042492175 @default.
- W2560484890 hasAuthorship W2560484890A5057316768 @default.
- W2560484890 hasAuthorship W2560484890A5069302338 @default.
- W2560484890 hasConcept C121608353 @default.
- W2560484890 hasConcept C126322002 @default.
- W2560484890 hasConcept C128240485 @default.
- W2560484890 hasConcept C167734588 @default.
- W2560484890 hasConcept C170493617 @default.
- W2560484890 hasConcept C171122931 @default.
- W2560484890 hasConcept C180361614 @default.
- W2560484890 hasConcept C201750760 @default.
- W2560484890 hasConcept C2022786 @default.
- W2560484890 hasConcept C203014093 @default.
- W2560484890 hasConcept C2775960820 @default.
- W2560484890 hasConcept C2777025900 @default.
- W2560484890 hasConcept C2778439243 @default.
- W2560484890 hasConcept C2778461978 @default.
- W2560484890 hasConcept C2778729363 @default.
- W2560484890 hasConcept C2778820342 @default.
- W2560484890 hasConcept C2778903051 @default.
- W2560484890 hasConcept C2779490328 @default.
- W2560484890 hasConcept C28328180 @default.
- W2560484890 hasConcept C502942594 @default.
- W2560484890 hasConcept C71924100 @default.
- W2560484890 hasConcept C86803240 @default.
- W2560484890 hasConcept C95444343 @default.
- W2560484890 hasConceptScore W2560484890C121608353 @default.
- W2560484890 hasConceptScore W2560484890C126322002 @default.
- W2560484890 hasConceptScore W2560484890C128240485 @default.
- W2560484890 hasConceptScore W2560484890C167734588 @default.
- W2560484890 hasConceptScore W2560484890C170493617 @default.
- W2560484890 hasConceptScore W2560484890C171122931 @default.
- W2560484890 hasConceptScore W2560484890C180361614 @default.
- W2560484890 hasConceptScore W2560484890C201750760 @default.
- W2560484890 hasConceptScore W2560484890C2022786 @default.
- W2560484890 hasConceptScore W2560484890C203014093 @default.
- W2560484890 hasConceptScore W2560484890C2775960820 @default.
- W2560484890 hasConceptScore W2560484890C2777025900 @default.
- W2560484890 hasConceptScore W2560484890C2778439243 @default.
- W2560484890 hasConceptScore W2560484890C2778461978 @default.
- W2560484890 hasConceptScore W2560484890C2778729363 @default.
- W2560484890 hasConceptScore W2560484890C2778820342 @default.
- W2560484890 hasConceptScore W2560484890C2778903051 @default.
- W2560484890 hasConceptScore W2560484890C2779490328 @default.
- W2560484890 hasConceptScore W2560484890C28328180 @default.
- W2560484890 hasConceptScore W2560484890C502942594 @default.
- W2560484890 hasConceptScore W2560484890C71924100 @default.
- W2560484890 hasConceptScore W2560484890C86803240 @default.
- W2560484890 hasConceptScore W2560484890C95444343 @default.
- W2560484890 hasIssue "21" @default.
- W2560484890 hasLocation W25604848901 @default.
- W2560484890 hasOpenAccess W2560484890 @default.
- W2560484890 hasPrimaryLocation W25604848901 @default.
- W2560484890 hasRelatedWork W1989679112 @default.
- W2560484890 hasRelatedWork W2007338968 @default.
- W2560484890 hasRelatedWork W2058707578 @default.
- W2560484890 hasRelatedWork W2112064600 @default.
- W2560484890 hasRelatedWork W2274164992 @default.
- W2560484890 hasRelatedWork W2411841147 @default.
- W2560484890 hasRelatedWork W2560484890 @default.
- W2560484890 hasRelatedWork W4283690075 @default.
- W2560484890 hasRelatedWork W4361255046 @default.
- W2560484890 hasRelatedWork W4361255239 @default.
- W2560484890 hasVolume "116" @default.
- W2560484890 isParatext "false" @default.
- W2560484890 isRetracted "false" @default.
- W2560484890 magId "2560484890" @default.
- W2560484890 workType "article" @default.